



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07H 19/04, 19/06, 21/00		A1	(11) International Publication Number: WO 00/56747
			(43) International Publication Date: 28 September 2000 (28.09.00)
(21) International Application Number: PCT/GB00/00965 (22) International Filing Date: 15 March 2000 (15.03.00) (30) Priority Data: 9906328.1 19 March 1999 (19.03.99) GB (71) Applicant (for all designated States except US): AVECIA LIMITED [GB/GB]; Hexagon House, Blackley, Manchester M9 8ZS (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): REESE, Colin, Bernard [GB/GB]; King's College London, The Strand, London WC2R 2LS (GB). SONG, Quanlai [CN/US]; Apartment 300, 586 E. Barham Drive, San Marcos, CA 92078 (US). (74) Agents: REVELL, Christopher et al.; AVECIA Limited, Intellectual Property Group, Hexagon House, P.O. Box 42, Blackley, Manchester M9 8ZS (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.	
(54) Title: 2'-SUBSTITUTED RNA PREPARATION			
<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>(1)</p> </div> <div style="text-align: center;">  <p>(2)</p> </div> </div>			
(57) Abstract <p>A process for the preparation of a compound of formula (1) is provided, which comprises the reaction a compound of formula (2) with a compound of formula $Al(OR)_3$ wherein R is as defined above, under substantially anhydrous conditions. X, and X' are each independently H or a protecting group, B is a base; R is an alkyl, alkoxyalkyl, alkenyl, or alkynyl group, each of which may be optionally substituted, and L is a leaving group.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

2'-SUBSTITUTED RNA PREPARATION

The present invention relates to a process for preparing 2'-O-substituted nucleosides, and more particularly to a process for the preparation of 2'-O-substituted uridine and cytidine.

The possibility that synthetic oligonucleotides might be effective inhibitors of gene expression and be used as chemotherapeutic agents has stimulated much research work in recent years. In order to avoid their degradation by cellular nucleases, it is essential that such oligonucleotides should be modified. Modifications can be made to the internucleotide linkages, the base residues and the sugar residues. A large number of oligonucleotide analogues in which the internucleotide linkages have been modified, especially as phosphorothioates with non-bridging sulphur atoms, have been described. Several of these phosphorothioate analogues are promising drug candidates that are now undergoing clinical trials. However, phosphorothioates do have some disadvantages. Thus, they do not display optimal RNA-binding properties and they also have a tendency to bind to proteins in a non-specific manner. Possible base modifications are clearly limited as they must not lead to a significant decrease in hybridisation properties. Recently, considerable interest has been directed towards the modification of the sugar residues. One particular type of modification involves the introduction of 2'- α -alkoxy groups (as in 2'-O-alkyl-oligoribonucleotides). While, in general, small alkoxy groups (such as methoxy) promote better hybridisation properties with complementary ribonucleic acids (RNA), nuclease resistance tends to increase with an increase in the size of the alkoxy group. 2-Methoxyethoxy has emerged as an alkoxy group that confers both good hybridisation properties and high nuclease resistance. It therefore seems likely that 2'-O-(2-methoxyethyl)-ribonucleosides will be incorporated into a second generation of potential oligonucleotide chemotherapeutic agents. For this reason, the development of convenient methods for the preparation of 2'-O-(2-methoxyethyl)-ribonucleosides has become a matter of much importance.


The preparation of 2'-O-(2-methoxyethyl)-ribonucleosides, starting from D-ribose, has previously been described. These preparations involved the use of protecting groups and required a relatively large number of steps. For example, 2'-O-(2-methoxyethyl)-5-methyluridine was prepared by Martin, P. *Helv. Chim. Acta* 1995, 78, 486-504 from D-ribose in 10 steps and in 33% overall yield. A later report by McGee and Zhai in Abstracts of American Chemical Society National Meeting, Division of Organic Chemistry, March 1996 paper 253 revealed a much more convenient procedure for the preparation of 2'-O-alkyl derivatives of the main pyrimidine ribonucleosides. Thus, when 5'-O-(4,4'-dimethoxytrityl)-2,2'-anhydro-1- β -D-arabinofuranosyluracil was heated with magnesium methoxide in N,N-dimethylformamide (DMF) at 100°C, 5'-O-(4,4'-dimethoxytrityl)-2'-O-methyluridine was obtained in 94% yield. Somewhat lower yields of the corresponding 5'-

O-ethyl-, 5'-O-(n-propyl)- and 5'-O-allyl-uridine derivatives were obtained in the reactions between the same substrate and the appropriate magnesium alkoxides. It was also reported that magnesium alkoxides could be replaced by calcium alkoxides.

Ross et al reported in Nucleosides and Nucleotides, 1997, 16, 1641-3 that when unprotected 2,2'-anhydro-1- β -D-arabinofuranosyluracil was heated with a twofold excess of trimethyl borate and a stoichiometric quantity of trimethyl orthoformate in methanol at 150°C, under pressure, for 42 h, 2'-O-methyluridine was obtained in 86% isolated yield. 2'-O-Methyl-5-methyluridine was similarly prepared from 2,2'-anhydro-5-methyl-(1- β -D-arabinofuranosyluracil) by the borate ester procedure and, although no experimental details were provided, the preparation of 2'-O-methylcytidine was also reported. The yield of 2'-O-alkyl-uridine was stated to decrease with increasing alcohol size.

It remains desirable to identify additional or alternative routes for the preparation of 2'-O-substituted nucleosides.

According to the present invention, there is provided a process for the preparation of a compound of formula (1):




wherein:

X, and X' are each independently H or a protecting group;

B is a base; and

R is an alkyl, alkoxyalkyl, alkenyl, or alkynyl group, each of which may be optionally substituted;

which comprises reacting a compound of formula (2):



wherein

L is a leaving group; and

B, X and X' are as defined above

with a compound of formula $Al(OR)_3$ wherein R is as defined above, under substantially anhydrous conditions.

When R is alkenyl, the alkenyl group is often a C_{1-4} alkenyl group, especially an allyl or crotyl group. When R represents alkyl, the alkyl group is preferably a C_{1-4} alkyl, and most preferably a methyl or ethyl group. When R represents alkoxyalkyl, the alkoxyalkyl group is often a C_{1-4} alkoxy C_{1-4} alkyl group, and preferably a methoxyethyl group. When R is alkynyl, the alkynyl group is often a C_{1-4} alkynyl group, especially a

propargyl group. The alkyl, alkenyl, alkynyl and alkoxyalkyl groups may themselves be substituted by one or more substituents, particularly halogen, especially F, Cl or Br, and amino substituents.

5 Examples of protecting groups which can be represented by X and X' include acid labile protecting groups, particularly trityl and substituted trityl groups such as dimethoxytrityl and 9-phenylxanthen-9-yl groups; acid-labile acetal protecting groups, particularly 1-(2-fluorophenyl)-4-methoxypiperidine-4-yl (Fmp); and base labile-protecting groups such as acyl groups, commonly comprising up to 16 carbon atoms, such as ethanoyl groups or fatty alkanoyl groups, including particularly linear or branched C₆₋₁₆ alkanoyl groups, such as lauroyl groups; benzoyl and substituted benzoyl groups, such as alkyl, commonly C₁₋₄ alkyl-, and halo, commonly chloro or fluoro, substituted benzoyl groups.

10 Other suitable protecting groups include those derived from gamma keto acids, such as levulinoyl groups and substituted levulinoyl groups. Substituted levulinoyl groups include 5-halo-levulinoyl, such as 5,5,5-trifluorolevulinoyl and benzoylpropionyl groups; and silyl and siloxane ethers, such as alkyl, commonly C₁₋₄ alkyl, and aryl, commonly phenyl, silyl ethers, particularly trialkylsilyl groups, often tri(C₁₋₄-alkyl)silyl groups, such as tertiary butyl dimethyl silyl and tertiary butyl diphenyl silyl groups.

15 Bases which can be represented by B include nucleobases, particularly purines, especially adenine (A) and guanine (G); and pyrimidines, especially thymine (T), cytosine (C), and uracil (U); and substituted derivatives thereof. Examples of substituents which may substitute the bases, in addition to protecting groups, include alkyl, especially C₁₋₄-alkyl, particularly methyl; halogen, particularly Cl or Br; amino; alkenyl, especially C₁₋₄-alkenyl and particularly allyl; alkoxyalkyl, especially C₁₋₄alkoxyC₁₋₄alkyl, particularly methoxyalkyl; and alkynyl, particularly propargyl, substituents. The alkyl, alkenyl, alkynyl and alkoxyalkyl groups may themselves be substituted by one or more substituents, particularly halogen, especially F, Cl or Br, and amino substituents.


20 In addition to the presence of protecting groups X and X', bases employed in present invention may also be protected where necessary by suitable protecting groups. Protecting groups employed are those known in the art for protecting such bases. For example, A and/or C can be protected by benzoyl, including substituted benzoyl, for example alkyl- or alkoxy-, often C₁₋₄ alkyl- or C₁₋₄alkoxy-, benzoyl; pivaloyl; and amidine, particularly dialkylaminomethylene, preferably di(C₁₋₄-alkyl) aminomethylene such as dimethyl or dibutyl aminomethylene. G may be protected by a phenyl group, including substituted phenyl, for example 2,5-dichlorophenyl and also by an isobutyryl group. T and U generally are not protected, but in certain embodiments they may advantageously be protected, for example at O4 by a phenyl group, including substituted phenyl, for example 2,4-dimethylphenyl or at N3 by a pivaloyloxymethyl, benzoyl, alkyl or alkoxy substituted benzoyl, such as C₁₋₄ alkyl- or C₁₋₄ alkoxybenzoyl.

In certain embodiments, X and X' comprise a single protecting group which protects both the 3' and 5' positions. Examples of such groups include disiloxanes, especially tetraalkyldisiloxanes, such as tetraisopropylidisiloxane.

Leaving groups which can be represented by L include those leaving groups which can be displaced by a nucleophile of formula RO^- . Examples of preferred leaving groups include groups of formula $-\text{OSO}_2\text{CH}_3$, $-\text{OSO}_2\text{CF}_3$, Cl, Br, I, O-Mesyl, O-Brosyl and O-Tosyl groups.

In certain preferred embodiments, the leaving group comprises the base, B, chemically bonded to the 2'-position, commonly via an oxygen or sulphur atom or a group of formula $-\text{NR}^x$, wherein R^x is H or a C_{1-6} alkyl or aryl, such as a phenyl, group. Most preferably, the base is uracil bonded to the 2'-position via an oxygen atom.

Accordingly, a second aspect of the present invention provides a process for the preparation of a compound of formula (3):




wherein:

X and X' are as defined above;

R^1 and R^2 are each independently H, alkyl, alkenyl, alkynyl, or halogen; and

R is an alkyl, alkoxyalkyl, alkenyl, or alkynyl group, each of which may be optionally substituted;

which comprises the reaction of a compound of formula (4)



wherein

X, X', R^1 and R^2 are as defined above;

with a compound of formula $\text{Al}(\text{OR})_3$ wherein R is as defined above, under substantially anhydrous conditions.

When either of R^1 and R^2 is alkenyl, the alkenyl group is often a C_{1-4} alkenyl group, especially an allyl or crotyl group. When either of R^1 and R^2 represents alkyl, the alkyl group is preferably a C_{1-4} alkyl, and most preferably a methyl or ethyl group. When either

of R¹ and R² represents alkoxyalkyl, the alkoxyalkyl group is often a C₁₋₄ alkoxyC₁₋₄ alkyl group, and preferably a methoxyethyl group. When either of R¹ and R² is alkynyl, the alkynyl group is often a C₁₋₄ alkynyl group, especially a propargyl group. The alkyl, alkenyl and alkynyl groups represented by R¹ or R² may be substituted by one or more substituents, particularly halogen, especially F, Cl or Br, and amino substituents. When either of R¹ and R² is halogen the halogen is preferably Cl, Br or I. Most preferably, both of R¹ and R² represent H, or R¹ represents C₁₋₄ alkyl and R² represents H.

The process according to the present invention takes place in the presence of a suitable substantially anhydrous solvent. Examples of suitable solvents include halocarbons such as chloroform, 1,2-dichloroethane and chlorobenzene; esters, particularly alkyl esters such as ethyl acetate, and methyl or ethyl propionate; amides such as N-methylpyrrolidinone, dimethylformamide and particularly dimethylacetamide; lower alkyl, for example C₂₋₄ nitriles such as acetonitrile; ethers such as glyme and diglyme and cyclic ethers such as tetrahydrofuran and dioxane; tertiary amines, such as N-methylpyrrolidine and heterocyclic aromatic amines such as pyridine. and alcohols, most commonly the alcohol corresponding to the group R, for example methanol, ethanol, methoxyethanol, allyl alcohol or propargyl alcohol.

The process of the present invention is often carried out at a temperature of from room temperature, such as about 25°C, up to the reflux temperature of the solvent employed. Temperatures above the normal boiling point of the solvent employed can be employed if desired by carrying out the process under super-atmospheric pressure conditions, for example in a sealed reaction vessel. Commonly, the temperature is in the range of from 50 to 150°C.

The process commonly takes place over a period ranging from several hours, for example from 4 to 12 hours, to several days, for example from 1 to 2 days, depending on the reagents and reaction conditions employed.

When the compound of formula (1) comprises the base uracil, the uracil moiety may be converted to a cytosine moiety. Similarly, the uracil moiety comprised in the compound of formula (3) may also be converted to a cytosine moiety. The skilled man will recognise that a number of different techniques can be employed. Examples of such techniques include:

- a) the nitrophenyl route (see Miah et al, Nucleosides and Nucleotides, 1997, 16, pp53-65) where for example the uracil containing compound is reacted with chlorotrimethylsilane in acetonitrile/1-methylpyrrolidine, then with trifluoroacetic anhydride, followed by 4-nitrophenol. The 4-nitrophenol moiety is then displaced with ammonia in aqueous dioxane to yield the cytosine-containing compound; and
- b) the triazolation procedure, (see Divakar et al, J. Chem. Soc. Perkin Trans. 1, 1982, 1171-6) where for example the uracil containing compound is reacted with acetic anhydride in pyridine, then, after work up, with phosphoryl chloride, 1,2,4-triazole and

triethylamine in acetonitrile to give the 4-triazolopyrimidine. The triazole moiety is then displaced with ammonia in aqueous dioxane, and acetyl groups removed to yield the cytosine-containing compound.

5 Protecting groups can be removed using methods known in the art for the particular protecting group and function. For example, acyl protecting groups, such as ethanoyl and benzoyl groups, can be removed by treatment with a solution of ammonia in an alcohol such as ethanol.

Benzoyl, pivaloyl and amidine groups can be removed by treatment with concentrated aqueous ammonia.

10 Trityl groups present can be removed by treatment with acid, for example a solution of dichloroacetic acid in dichloromethane. With regard to the overall unblocking strategy an important consideration is that the removal of trityl, often DMTr, protecting groups ('deprotection') should proceed without concomitant depurination when base B represents a purine, especially adenine. Such depurination can be suppressed by
15 effecting 'deprotection' with a dilute solution of hydrogen chloride at low temperature, particularly ca. 0.45 M hydrogen chloride in dioxane - dichloromethane (1:8 v/v) solution at -50°C. Under these reaction conditions, 'deprotection' can be completed rapidly, and in certain cases after 5 minutes or less.

20 Silyl protecting groups may be removed by fluoride treatment, for example with a solution of a tetraalkyl ammonium fluoride salt such as tetrabutyl ammonium fluoride.

Fmp protecting groups may be removed by acidic hydrolysis under mild conditions.

Compounds produced by the present invention may be incorporated in the assembly of a desired oligonucleotide by coupling with other nucleosides or
25 oligonucleotides (which may themselves have been prepared using the present invention) and such a process forms a further aspect of the present invention. The coupling processes employed are those known in the art for the preparation of oligonucleotides.

The present invention is further illustrated, but not limited by, the following Examples.

30

General Experimental Details

Mps are uncorrected. ¹H and ¹³C NMR spectra were measured at 360.1 and 90.6 MHz respectively, with a Bruker AM 360 spectrometer; tetramethylsilane was used as an internal standard. TLC was carried out with Merck silica gel 60 F₂₅₄ pre-coated plates (Art 5715), which were developed in solvent system A [CHCl₃-MeOH (85:15 v/v)]. Short
35 column chromatography was carried out on silica gel (Merck Art 7729). Acetonitrile and 1-methylpyrrolidine were dried by heating, under reflux, with calcium hydride and were then distilled. N,N-Dimethylacetamide (DMA) was dried by distillation over calcium hydride under reduced pressure. 2-Methoxyethanol was dried by heating with aluminium

foil (1g/250ml), under reflux, and was then distilled. Diethyl ether was dried over sodium wire.

Preparation of 2,2'-Anhydro-1- β -D-arabinofuranosyluracil

5 Uridine (12.21g, 50mmol), diphenyl carbonate (11.79g, 55mmol), sodium hydrogen carbonate (0.21g, 2.5mmol) and dry DMA (10ml) were heated together, with stirring, at 100°C. After 5h, the products were cooled to room temperature, and diethyl ether (100ml) was added with stirring. After 2 hours, the colourless precipitate (11.70g) was collected by filtration and was washed with ether (2 x 50ml). The sole nucleoside
10 constituent of the precipitated material was identified as 2,2'-anhydro-1- β -D-arabinofuranosyluracil (calculated quantitative yield, 11.31g) by comparison with authentic material.

Preparation of 2'-O-(2-Methoxyethyl)uridine

15 Aluminium foil (3.64g, 0.135 mol) and dry 2-methoxyethanol (135ml) were heated, under reflux, for ca. 1hr until all of the aluminium had been consumed. Crude (see above) 2,2'-anhydro-1- β -D-arabinofuranosyluracil (10.18g, ca. 43.5 mmol) was added and the reactants were heated, under reflux, for 48 hours. Absolute ethanol (200ml), followed by water (7.3ml, 0.405mol) and Celite were added to the cooled products. The resulting
20 mixture was heated, under reflux, for 10 minutes and was then filtered. The residue was washed with ethanol (3 x 100ml). The combined filtrate and washings were evaporated under reduced pressure to give a pale yellow solid. The material was purified by short column chromatography on silica gel (70g): the appropriate fractions, which were eluted with dichloromethane-methanol (90:10 v/v), were evaporated under reduced pressure to
25 give the title compound as a colourless solid (12.05g, ca. 91%).


Preparation of 2'-O-(2-Methoxyethyl)cytidine

2'-O-(2-Methoxyethyl)uridine (6.05g, 20.0mmol), 1-methylpyrrolidine (20ml, 0.192mol), chlorotrimethylsilane (7.6ml, 59.9mmol) and dry acetonitrile (100ml) were
30 stirred together at room temperature. After 1 hour, the reactants were cooled to 0°C (ice-water bath) and trifluoroacetic anhydride (7.1ml, 50.3 mmol) was added dropwise over 5 minutes. After a further period of 30 minutes at 0°C, 4-nitrophenol (8.35g, 60mmol) was added to the stirred reactants which were maintained at 0°C. After 3 hours, the products were poured into saturated aqueous sodium hydrogencarbonate (200ml), and the
35 resulting mixture was extracted with dichloromethane (3 x 100ml). The combined organic layers were dried (MgSO₄), and evaporated under reduced pressure. Concentrated aqueous ammonia (d 0.88, 20ml) was added to a stirred solution of the residue in dioxane (100ml), contained in a sealed flask that was then heated at 55°C for 24 hours. The resulting yellow solution was concentrated under reduced pressure, and the residue was

evaporated with absolute ethanol (3 x 50ml). The products were fractionated by short column chromatography on silica gel: the appropriate fractions, which were eluted with dichloromethane-methanol-triethylamine (93:7:0.5 to 90:10:0.5 v/v) were evaporated under the reduced pressure to give the title compound as an off-white solid (5.07g 84%).

CLAIMS

1. A process for the preparation of a compound of formula (1):




5 wherein:

X, and X' are each independently H or a protecting group;

B is a base; and

R is an alkyl, alkoxyalkyl, alkenyl, or alkynyl group, each of which may be optionally substituted;

- 10 which comprises reacting a compound of formula (2):



wherein


L is a leaving group; and

B, X and X' are as defined above

- 15 with a compound of formula $Al(OR)_3$, wherein R is as defined above, under substantially anhydrous conditions.

2. A process according to claim 1, wherein the leaving group is selected from the group consisting of $-OSO_2CH_3$, $-OSO_2CF_3$, Cl, Br, I, O-Mesyl, O-Brosyl, O-Tosyl and the base, B, chemically bonded to the 2'-position, via an oxygen or sulphur atom or a moiety of formula $-NR^x$, wherein R^x is H or a C_{1-6} alkyl or an aryl group.

3. A process for the preparation of a compound of formula (3):




25 wherein:

X, and X' are each independently H or a protecting group;;

R¹ and R² are each independently H, alkyl, alkenyl, alkynyl, or halogen; and

R is an alkyl, alkoxyalkyl, alkenyl, or alkynyl group, each of which may be optionally substituted;

which comprises the reaction of a compound of formula (4)



5 wherein

X, X', R¹ and R² are as defined above;

with a compound of formula $Al(OR)_3$ wherein R is as defined above, under substantially anhydrous conditions.

10

4. A process according to claim 3, wherein R¹ and R² are both H, or R¹ is C₁₋₄ alkyl, and R² is H.

5. A process according to any preceding claim, wherein R is a C₁₋₄ alkenyl group, a C₁₋₄ alkyl group, a C₁₋₄ alkoxyC₁₋₄ alkyl group or a C₁₋₄ alkynyl group.

15

6. A process according to claim 5, wherein R is a methoxyethyl group.

7. A process for the preparation of a compound of Formula (1) wherein B represents cytosine, or a substituted derivative thereof, which comprises:

20

a) preparing a compound of Formula (1) wherein B represents uracil, or a substituted derivative thereof, by a process according to claim 1; and

b) converting the uracil moiety to the equivalent cytosine moiety; or

c) preparing a compound of Formula (3) by a process according to claim 2; and

d) converting the uracil moiety therein to a cytosine moiety.

25

8. A process for the preparation of a product oligonucleotide which comprises the coupling to a nucleoside or an oligonucleotide of a compound prepared by a process according to any one preceding claim.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/00965

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07H19/04 C07H19/06 C07H21/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 27606 A (ISIS PHARMACEUTICALS INC ;COOK PHILLIP DAN (US); SANGHVI YOGESH S) 12 September 1996 (1996-09-12) page 33; claims 1-55	1
A	MCGEE D P C ET AL: "REACTION OF ANHYDRONUCLEOSIDES WITH MAGNESIUM ALKOXIDES: REGIOSPECIFIC SYNTHESIS OF 2'-O-ALKYLPYRIMIDINE NUCLEOSIDES" NUCLEOSIDES & NUCLEOTIDES,US,MARCEL DEKKER, INC, vol. 15, no. 11/12, 1 January 1996 (1996-01-01), pages 1797-1803, XP002066801 ISSN: 0732-8311 abstract	1

-/-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "S" document member of the same patent family

Date of the actual completion of the international search

8 May 2000

Date of mailing of the international search report

23/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scott, J

INTERNATIONAL SEARCH REPORT

Int. .onal Application No

PCT/GB 00/00965

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>B.S.ROSS ET AL.: "A Novel and Economical Synthesis of 2'-O-Alkyl-Uridines." NUCLEOSIDES & NUCLEOTIDES., vol. 16, no. 7-9, 1997, pages 1641-1643, XP002137095 MARCEL DEKKER, INC., US ISSN: 0732-8311 the whole document</p>	1

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 00/00965

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9627606 A	12-09-1996	US 5760202 A	02-06-1998
		AU 5359496 A	23-09-1996
		CA 2214535 A	12-09-1996
		EP 0813539 A	29-12-1997
		JP 10512894 T	08-12-1998
		NO 974077 A	22-10-1997
		US 5861493 A	19-01-1999